Diagnosis and management of binge eating disorder by Bulik, Cynthia M. et al.
142 World Psychiatry 6:3 - October 2007
Diagnosis and management of binge eating disorder
SPECIAL ARTICLE
CYNTHIA M. BULIK1,2, KIMBERLY A. BROWNLEY1, JENNIFER R. SHAPIRO1
1Department of Psychiatry and 2Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7160, USA
The symptom of binge eating was first identified by
Stunkard in 1959 (1). However, the syndrome of binge eat-
ing disorder (BED) has not yet achieved official diagnostic
recognition and remains a syndrome in need of further
study in the DSM-IV-TR (2).
DIAGNOSIS OF BED: CONTROVERSIES
AND EVOLVING ASSESSMENT STRATEGIES
The diagnostic criteria for BED are listed in Table 1.
Similar to bulimia nervosa (BN), the definition of a binge
eating episode requires the consumption of an unusually
large amount of food coupled with a sense of feeling out of
control. Also as in BN, the frequency criterion is twice per
week, although this criterion is not well supported by the
literature for BN and has not been validated for BED (3,4).
Where BN and BED diverge is that individuals with BED
do not regularly engage in compensatory behaviors (i.e.,
purging, laxative abuse, excessive exercise), although the
precise boundary between BED and non-purging BN is far
from clear. In addition, to meet criteria for BED, the binge
episodes are associated with at least three of the following
criteria: a) eating more rapidly than normal; b) eating when
not physically hungry; c) eating until uncomfortably full; d)
eating alone because of shame; and e) feeling disgusted
with oneself, depressed or guilty after overeating (2). Fi-
nally, the individual experiences marked distress regarding
binge eating. Although some of these criteria date back to
the DSM-III criteria for bulimia, none have been empiri-
cally validated for BED.
Given the concern with proliferation of categories in the
DSM, experts have proposed guidelines to consider before
adding a syndrome to the DSM. Blashfield et al (5) pro-
posed five taxonomic guidelines: a) there should be suffi-
cient journal and empirical articles published on the pro-
posed syndrome within the last 10 years; b) explicit diag-
nostic criteria should have been proposed in the literature
and measurement procedures exist for assessing the syn-
drome; c) at least two empirical studies (by independent re-
search groups) demonstrate good inter-rater reliability; d)
the category represents a syndrome of frequently co-occur-
ring symptoms; and e) at least two independent, empirical
studies demonstrate that the proposed category can be dif-
ferentiated from other categories with which it may be con-
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Table 1 DSM-IV-TR diagnostic criteria for binge eating disorder
A. Recurrent episodes of binge eating
An episode of binge eating is characterized by both of the following:
1. Eating, in a discrete period of time (e.g., within any 2-hour period), an
amount of food that is definitely larger than most people would eat in a
similar period of time under similar circumstances
2. The sense of lack of control over eating during the episode (e.g., a feeling
that one cannot stop eating or control what or how much one is eating)
B. Binge-eating episodes are associated with three (or more) of the following:
1. Eating much more rapidly than normal 
2. Eating until feeling uncomfortably full
3. Eating large amounts of food when not feeling physically hungry
4. Eating alone because of being embarrassed by how much one is eating
5. Feeling disgusted with oneself, depressed, or very guilty after overeating
C. Marked distress regarding binge eating is present
D. The binge eating occurs, on average, at least 2 days a week for 6 months
(Note: The method of determining frequency differs from that used for bulimia
nervosa; future research should address whether the preferred method of setting
a frequency threshold is counting the number of days on which binges occur or
counting the number of episodes of binge eating)
E. The binge eating is not associated with the regular use of inappropriate
compensatory behavior (e.g., purging, fasting, excessive exercise, etc.) and does
not occur exclusively during the course of anorexia nervosa or bulimia nervosa
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fused. Although substantial work has been done on BED,
not all of these guidelines have been adequately addressed. 
Over the past decade, the magnitude of research focus-
ing on BED has increased substantially (6). A variety of self-
report inventories, such as the Binge Eating Scale (BES) (7),
the Three Factor Eating Questionnaire (8) and the Body
Shape Questionnaire (9), as well as interview methods,
such as the Structured Clinical Interview for the Diagnosis
of DSM Disorders (SCID, 10) and the Eating Disorders Ex-
amination (EDE) (11), have been developed to assess binge
eating in adults. However, attempts are still ongoing to re-
fine the definition of a binge episode and to develop valid
and reliable diagnostic criteria for BED. Researchers and
clinicians are often unsuccessful in assessing what is an un-
usually large amount of food (12). First, they are inconsist-
ent in recognizing bouts of overeating from grazing (i.e.,
eating continuously throughout the day instead of eating
planned meals) and in deciphering what constitutes a truly
large portion size from normal behavior, overindulgence, or
circumstances (e.g., holiday). These inconsistencies make it
difficult to determine the true number of binge episodes ex-
perienced by a patient or research participant. Second, re-
searchers and clinicians (as well as patients) are unreliable
in determining if loss of control was present during the
binge eating episode (12). Because of subjective differences
in the definition, loss of control is difficult to measure.
Some individuals may report loss of control after eating a
small amount of food (e.g., one cookie), whereas others
may only experience a sense of loss of control after a much
larger amount of food (e.g., a box of cereal). The EDE has a
method for classifying types of overeating. An objective
binge episode is one in which the amount eaten would be
defined as relatively large (judged by the interviewer) and
includes the patient’s report of loss of control during the
episode. A subjective binge episode is not viewed as large
by the interviewer but the patient still reports loss of con-
trol. For example, the patient may have eaten a regular size
candy bar but may have intended to only eat half of it. Al-
ternatively, subjects may be classified with overeating
episodes (either objective or subjective) when they do not
experience loss of control over eating.
Although initially conceptualized primarily to be a dis-
order of adulthood, there is growing recognition that BED
also occurs in adolescents and children. Such recognition
has propelled the development of age-appropriate and age-
relevant assessment measures. Assessment measures for
children include the Eating Disorders Examination adapt-
ed for children (ChEDE) (13) and the Questionnaire of Eat-
ing and Weight Patterns - Adolescent version (14). Research-
ers have posited that broader, flexible criteria be used to
measure BED in children (15-17), and Marcus and
Kalarchian (15) recently proposed provisional criteria for
measuring BED in children (see Table 2) based on a review
and synthesis of findings from previous research studies.
On the basis of these criteria, Shapiro et al (18) developed
a brief structured, interviewer-administered scale (Chil-
dren’s Binge Eating Disorder Scale, C-BEDS) to measure
BED in children aged 5-13. Results showed a strong asso-
ciation between diagnoses from the C-BEDS and SCID.
However, the C-BEDS may be more developmentally ap-
propriate for children and better able to identify subsyn-
dromal BED. If used by physicians and other health
providers, this brief measure may assist with identifying
early onset binge eating behaviors and avoiding the associ-




The primary goal for BED treatment is to achieve absti-
nence from binge eating. In overweight individuals with
BED, treatment goals are often twofold: abstinence from
binge eating and sustainable weight loss. Given comorbid-
ity profiles, treatment must also often target anxiety and de-
pression commonly associated with BED.
The literature on BED treatment covers a wide range of
putative therapeutic agents and modalities. Those with the
most substantial empirical support to date include the use
of certain medications and certain behavioral interven-
tions, alone or in combination. Evidence supporting self-
help and other approaches is less strong (19,20). 
Treatment approaches
Pharmacotherapy
The medications most widely studied thus far in ran-
domized controlled trials (RCTs) include second-genera-
tion antidepressants (21-25), tricyclic antidepressants (26),
anticonvulsants (27), and sibutramine (28). However, the
majority of published RCTs have been limited in scope,
Table 2 Provisional research criteria for diagnosing binge eating
disorder in children (from 15)
A. Recurrent episodes of being eating
An episode of binge eating is characterized by both of the following:
1. Food seeking in absence of hunger (e.g. after a full meal)
2. A sense of lack of control over eating (e.g., endorse that ‘‘When I start to
eat, I just can’t stop’’)
B. Binge episodes are associated with one or more of the following:
1. Food seeking in response to negative affect (e.g., sadness, boredom, rest-
lessness)
2. Food seeking as a reward
3. Sneaking or hiding food
C. Symptoms persist over a period of 3 months
D. Eating is not associated with the regular use of inappropriate compensa-
tory behaviors (e.g., purging, fasting, excessive exercise) and does not occur ex-
clusively during the course of anorexia nervosa or bulimia nervosa
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with samples being relatively small (fewer than 500 total
participants in eight medication RCTs comprising primari-
ly Caucasian women over age 18). 
Among selective serotonin reuptake inhibitors (SSRIs),
fluoxetine and fluvoxamine have received the most attention
thus far. After 12 weeks, both fluoxetine (average dose 71.3
mg/day) (21) and fluvoxamine (average dose 239 mg/day)
(22) were associated with reduced binge frequency and de-
pressed mood. Using a larger sample (85 BED patients) but
a shorter treatment period (9 weeks), Hudson et al (24) re-
ported a significantly greater rate of reduction in binge fre-
quency and body mass index (BMI) as well as greater im-
provement in illness severity with fluvoxamine (50-300
mg/day) compared to placebo. However, fluvoxamine did
not demonstrate superiority over placebo in terms of remis-
sion rate or change in depression scores. Moreover, end-
point BMI was not reported. Thus, the group receiving flu-
voxamine experienced more rapid reductions in binge eat-
ing and weight than the placebo group, but these changes
did not appear to yield clinically significant effects with re-
spect to binge abstinence and weight loss. 
Sertraline and citalopram also show some promise in
the treatment of BED. In two 6-week treatment trials,
McElroy et al studied the effects of sertraline (mean dose
187 mg/day) versus placebo (23) and citalopram (40-60
mg/day) versus placebo (25) on binge frequency, weight,
and mood in individuals with BED. Compared with place-
bo, both sertraline and citalopram were associated with re-
duced binge eating, weight loss, and illness severity ratings,
but neither medication was clearly superior to placebo in
terms of remission rate, and the initial rapid response in
binge eating observed with citalopram was not sustained
over time. Citalopram, but not sertraline, was associated
with reduced depression ratings compared to placebo.
Tricyclic antidepressants are also of interest in the treat-
ment of BED. Laederach-Hoffmann et al (26) studied 31
overweight individuals with BED over a 32-week period,
providing standard bi-weekly diet counseling and psycho-
logical support augmented with either imipramine (25 mg
three times a day) or placebo. At 8 and 32 weeks, binge eat-
ing episodes, depressed mood, and body weight decreased
significantly in the imipramine-treated group. However,
abstinence rates from binge eating were not reported.
Medications that suppress appetite directly or that are as-
sociated with weight loss as a side effect have also been ex-
amined in the treatment of BED. Examples include the an-
ticonvulsant agent topiramate, which is associated with
weight loss in some patients, and sibutramine, which is
marketed for the treatment of obesity. In a recent study, top-
iramate (average dose 212 mg/day) was administered for 14
weeks to obese individuals with BED with a score greater
than 15 on the Yale-Brown Obsessive Compulsive Scale for
Binge Eating (YBOCS-BE) (27). Relative to placebo, topir-
imate yielded a significantly greater percentage reduction in
binge episodes, binge days per week, and YBOCS-BE score,
but did not differ with respect to weight loss, illness severi-
ty, or depression. Appolinario et al (28) studied the effects
of 12 weeks of sibutramine treatment (15 mg/day) in indi-
viduals with BED and a BES score of at least 17. The sibu-
tramine-treated group showed significantly greater decreases
in binge days per week, BES scores, and self-reported de-
pression scores compared to the placebo group. At week 12,
the sibutramine group had lost on average 7.4 kg, whereas
the placebo group had gained weight.
In summary, pharmacotherapy can be useful in the treat-
ment of BED. Specifically, certain second-generation anti-
depressants, anticonvulsants, and anti-obesity medications
have been associated with reduced binge frequency and in
some cases reduced negative affect in individuals with BED.
However, overall, studies have been hampered by high drop
out and placebo response rates and by the failure to meas-
ure abstinence as a primary outcome and to report long-
term post-intervention data. These limitations make it diffi-
cult to estimate the magnitude of clinical significance of any
observed effects attributed to medication. Further study will
be needed to determine the full utility and limitations of
pharmacotherapy in the treatment of BED.
Behavioral therapy
Cognitive-behavioral therapy (CBT) has been the most
commonly tested behavioral therapeutic approach for BED
(29-31). Other approaches include dialectical behavior ther-
apy (DBT), self-help, exercise, and virtual reality therapy
(32-38). Studies have examined the effect of CBT alone as
well as in combination with other manipulations concern-
ing the level of spousal or therapist involvement or comple-
mentary body exposure treatment. The majority of behavioral
therapy trials have enrolled relatively small samples of indi-
viduals with BED, usually female and over 18 years of age.
CBT for BED is rooted in the idea that inaccurate
thoughts (about body image, for example) lead to inappro-
priate food consumption (i.e., excess quantity in a short
time with accompanying feelings of loss of control), and
that learning to adjust or restructure one’s binge-triggering
thoughts can reduce binge behavior. CBT can be delivered
one-on-one or in a group setting, independently or in com-
bination with other psychotherapy approaches.
Several studies have shown that CBT reduces binge fre-
quency, related psychological aspects of binge eating (re-
straint, disinhibition, and hunger), depressed mood, and
ratings of illness severity in individuals with BED (29-31).
CBT may also increase the likelihood of abstinence from
binge eating (31). However, CBT does not appear to lead to
significant changes in body weight. Moreover, augmenta-
tion strategies such as CBT plus increased spousal involve-
ment with therapy (31) or body exposure treatment (30)
have not revealed any clear advantages over CBT alone.
Thus, as currently conceptualized, CBT may be effective in
helping patients improve their sense of control over binge
eating behavior, but not over their weight concerns.
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DBT fosters the development of skills in the domains of
mindfulness, emotion regulation, interpersonal effectiveness,
and distress tolerance. One study suggests that DBT princi-
ples may be useful in the management of BED. Telch et al
(32) studied 20 weeks of DBT versus waiting list control in
44 women with DSM-IV BED. DBT led to greater reduction
in binge days and binge episodes and in weight, shape, and
eating concerns. However, the two groups did not differ in
weight loss or in change in depression or anxiety.
Several studies have examined the effect of self-help
strategies in BED. Interventions have been delivered in var-
ious formats, including with and without a facilitator or ther-
apist, with or without structure, etc. Carter and Fairburn
compared self-help using a book (33) with waiting list con-
trol in 72 women with BED and weekly binges (34). Self-
help (both with and without a facilitator) led to greater re-
ductions in the mean number of binge days and in clinical
severity, while also improving abstinence and cessation rates
and EDE scores. However, self-help did not produce signif-
icant weight loss in either group. Adding a facilitator had no
appreciable effect over self-help alone. Similarly, Peterson et
al (35,36) found self-help, regardless of the degree of facili-
tator involvement, to be beneficial in terms of reduced binge
behavior, improved eating attitudes, and higher abstinence
rates, but not in terms of reducing depression scores or BMI.
Other “alternative” approaches such as exercise (37,38)
and virtual reality therapy (39) are beginning to be explored
in the treatment of BED, but currently sufficient data do
not exist to make any recommendations.
In summary, behavioral therapies offer some promise in
the treatment of BED. CBT, DBT and self-help approaches
are all associated with reductions in binge behavior, but the
clinical significance of these findings remains uncertain in
the absence of data on abstinence during active treatment
and longer-term follow-up. Moreover, as examined to date,
these behavioral therapies do not result in marked weight
loss, which is a critical concern for the significant number
of BED sufferers who are overweight. Somewhat paradoxi-
cally, there is some indication that drop out during self-help
intervention may be inversely related to the degree of in-
volvement by a professional facilitator/therapist. Further
studies are needed to clarify these observations.
Combining pharmacotherapy and behavioral therapy
Several studies have examined the potential benefit of
combining medication with behavioral treatment vs. either
therapy delivered alone in the management of BED.
In their 16-week trial, Grilo et al (40) compared fluoxe-
tine (60 mg/day) versus placebo either alone or with CBT.
Results indicated that CBT plus fluoxetine (as well as CBT
alone) was superior to fluoxetine alone and placebo in re-
mission rate and in reducing binge frequency, eating and
shape concerns, disinhibition, and depression. Weight loss
did not differ across groups, however.
Agras et al (41) evaluated the effects of traditional weight
loss therapy alone vs. CBT supplemented with weight loss
therapy vs. CBT supplemented with weight loss therapy
plus desipramine (300 mg/day). Binge eating was signifi-
cantly reduced after 12 weeks in both groups receiving CBT;
however, this effect did not persist at 36 weeks of treatment.
Average weight loss was greatest in the weight loss therapy
group in the early stages of treatment, but over time (i.e., at
3-month follow-up) the group receiving desipramine lost
the most weight. Desipramine showed no clear advantage
in reducing symptoms of depression.
Grilo et al (42) investigated the effect of CBT alone and
in combination with the lipase inhibitor orlistat (120 mg
three times/day) in 50 obese individuals with BED. CBT
plus orlistat was associated with greater initial weight loss
and a greater remission rate after 12 weeks of treatment.
However, these potential benefits were not accompanied by
any improvements in eating-related measures or depres-
sion, and they were not maintained at 2-month follow-up. 
Taken together, these studies suggest that augmentation
of CBT with certain medications may provide additional
benefit over CBT alone or medication alone strategies in
the early stages of BED treatment. However, the long-term
benefit of such combined approaches is less certain.
Treatment harms and factors contributing
to treatment efficacy
Throughout the BED treatment literature, the most com-
monly reported harms were those associated with the side
effects of second-generation antidepressants, such as seda-
tion, dry mouth, headache, and sexual dysfunction/de-
creased libido (43). In the studies reviewed here, for exam-
ple, compared to placebo, insomnia was more pronounced
in those receiving fluvoxamine or sertraline, and constipa-
tion was more pronounced in those receiving sibutramine
or imipramine. Other side effects, such as nausea, sweating
and fatigue, dry mouth, blurred vision, and gastrointestinal
upset, were also reported. Notably, 24% of individuals
treated with desipramine and 20% of individuals treated
with topiramate dropped out due to medication side effects.
Harms associated with psychotherapy are not reported as
frequently, but may include increased mood dysregulation
after cessation of active treatment, and should be monitored
and given appropriate attention.
Specific factors that contribute to treatment efficacy in
BED are not well understood. Limited data suggest that
early abstinence from binge eating is associated with sig-
nificantly greater weight loss (41), and that higher initial
self-esteem may account for a small but significant percent
of variance in outcome (33). There are deficiencies in the
research literature regarding treatment efficacy by sub-
groups, as well. In general, males, ethnic minorities, and
children are understudied. Initial findings require replica-
tion, and larger more culturally diverse samples need to be
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studied before an accurate picture of individual difference
factors in BED outcome can emerge.
Treatment drop out and placebo response
Our understanding of treatment options for BED is lim-
ited by several consistent methodological problems in the
research literature: drop out and placebo response rates that
are often high and unevenly distributed across treatment
groups, and the failure to report abstinence rates and long-
term follow-up data. Among pharmacotherapy trials re-
viewed here, drop out rates ranged from a low of 7% (with
imipramine) to a high of 57% (with fluoxetine); rates for
citalopram (16%), fluvoxamine (20%), sibutramine (23%),
orlistat (24%), sertraline (28%), and topiramate (47%) were
intermediate. Placebo response rates were also highly vari-
able (6% to 39%). In psychotherapy trials, drop out was al-
so extensive and highly variable, and not always consistent
with hypothesized effects of the therapeutic manipulation
(i.e., facilitator involvement). Across studies, drop out from
CBT (14% to 34% in studies reviewed), DBT (18%), and
self-help (0% to 27%) was on par with or perhaps slightly
lower compared to certain pharmacotherapies, particularly
fluoxetine, suggesting good acceptability of these treatment
approaches to most patients. Evidence that combination
therapies are more or less acceptable and tolerable for pa-
tients is mixed, including improved drop out from weight
loss therapy plus CBT vs. weight loss alone (41), but not
from treatment with fluoxetine plus CBT vs. fluoxetine
alone (40). Lastly, the vast majority of published treatment
trials have not followed participants for extended periods
after acute treatment ends, so that the utility of these inter-
ventions in the long-term management of BED is uncertain.
CONCLUSIONS
Several issues regarding the diagnosis and management
of BED remain open to research. Controversies in diagno-
sis include the lack of empirically validated criteria, the
lack of a universally recognized operational definition of a
“binge episode”, and the lack of age-appropriate assess-
ment instruments to be used in children and adolescents
with BED.
Short-term, placebo-controlled medication-only trials
provide limited evidence that SSRIs can be useful in re-
ducing target eating, psychiatric, and weight symptoms in
individuals with BED. However, this evidence must be
viewed tentatively, because it is derived from a collection
of studies plagued by high drop out and placebo response
rates. Non-SSRI agents such as sibutramine and topira-
mate may also be beneficial in terms of weight reduction
among individuals with BED, but definitive conclusions
about their longer-term clinical utility await further details
regarding abstinence and remission. Similarly, more stud-
ies are needed to confirm the therapeutic potential of low-
dose imipramine to augment more traditional weight man-
agement and psychotherapy strategies.
In terms of behavioral interventions, CBT is effective in
reducing binge frequency (whether reported as binge days
or binge episodes) and in improving the psychological fea-
tures of BED such as restraint, hunger, and disinhibition.
CBT’s effect on binge frequency, in particular, apparently
leads to greater rates of sustained (up to four months after
treatment) abstinence. The validity of CBT for reducing
symptoms of depression in this patient population is un-
clear. Likewise, additional studies are needed to confirm the
findings of decreased binge eating, eating-related psycho-
pathology, and negative mood with DBT. Self-help ap-
proaches may provide viable alternatives, as they have
shown efficacy in decreasing binge eating and key psycho-
logical features associated with BED. Abstinence from
binge eating may hinge on treatment expectancies about
weight loss and improved mood – the practitioner must be
savvy about these treatment limitations, convey them
through patient education, and monitor their impact on
long-term adherence. Although non-weight focused behav-
ioral strategies may not promote significant weight loss, they
may be associated with less weight gain over time in indi-
viduals with BED. The importance of weight maintenance
vs. weight loss or gain in treatment adherence and remission
warrants further study. Finally, to date, most behavioral
studies have suffered from marked drop out, thus our un-
derstanding of CBT as well as other behavioral therapies for
the treatment of BED is still limited. Specific unaddressed
questions include whether calories previously consumed as
binges become distributed over nonbinge meals after treat-
ment, which would contribute to the absence of weight
change in CBT, and whether treatment alters the way in
which patients label binges and nonbinge meals.
Questions remain as to the added benefit of combining
pharmacological and psychotherapy approaches (i.e., medi-
cation plus CBT), which improve both binge eating and
weight loss outcomes. Specifically, additional studies are
needed to determine which medications given under which
circumstances and to which patients optimally produce and
maintain weight loss. Because weight-loss medications gen-
erally exert their effects only during active treatment (44),
questions remain about pharmacotherapy duration and its
relation to remission of behavioral and psychological symp-
toms and to long-term weight outcome. In addition, further
studies are needed to better understand factors that serve as
binge triggers (i.e., food cravings, mood) (45).
In order to move our understanding of BED treatment
forward, new methods that enhance motivation and reten-
tion in medication trials need to be developed, and optimal
strategies for maintaining treatment gains must be deter-
mined. The metric by which we evaluate treatment success
must also be refined and standardized to focus on absti-
nence from binge eating (not merely reduced binge fre-
quency) as the critical outcome. In addition, abstinence
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should be evaluated independent of weight loss, yet weight
loss must not be overlooked as a potentially significant
moderator of long-term adherence and treatment satisfac-
tion. Studies that target relapse prevention in BED also
warrant a high research priority. Future studies should al-
so carefully document and control for placebo response,
which has been shown to be high (yet possibly transitory)
in BED (22,46,47). Advances regarding treatment-resistant
BED patients are likely to build on lessons learned from re-
cent depression-treatment trials regarding potential drug
augmentation and sequential medication benefits (48), and
from ongoing and future studies targeting CBT non-re-
sponders. Finally, additional studies of DBT (for example,
which can articulate which aspects of DBT are most appli-
cable to the complex emotional and behavioral features of
BED) are warranted.
Research is needed on innovative medications and be-
havioral treatments that explore novel modalities to reduce
the subjectively reinforcing properties of binge eating. This
likely includes new information technologies (such as e-
mail, the Internet, personal digital assistants, text messag-
ing, and other technological advances) that can be used to
enhance treatment, particularly for those patients experi-
encing shame, denial, and interpersonal deficits or facing
limited availability of specialty care. Our group (49) recent-
ly compared preliminary feasibility and acceptability of CD-
ROM-delivered cognitive-behavioral therapy (CD-ROM
CBT) to 10 weekly group CBT sessions and to a waiting list
control in 66 overweight individuals with BED. Results
were promising in terms of drop out and continued use of
the CD after treatment. Also, the majority of waiting list par-
ticipants elected to receive CD-ROM CBT over group CBT
treatment at the end of the waiting period. Thus, prelimi-
narily, CD-ROM appears to be an acceptable and at least
initially preferred method of CBT delivery for overweight
individuals with BED. The use of technology as a means of
treatment delivery is emerging (50); further studies are
needed in order to bridge the gap between clinical research
and population-based delivery for the treatment of BED.
In summary, individuals with BED can benefit from phar-
macotherapy and psychotherapy both alone and in combi-
nation. Greater clarity is required to determine how best to
achieve both abstinence from binge eating and sustainable
weight loss. As these stories unfold, important insights will
likely emerge regarding BED and its place within the broad-
er context of our current obesity epidemic (51,52).
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